Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.73 |
| ▸ | HTR2A | P28223 | 7/20 | 0.73 |
| ▸ | DRD4 | P21917 | 6/20 | 0.73 |
| ▸ | HTR1A | P08908 | 6/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.73 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.73 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.73 |
| ▸ | DRD1 | P21728 | 1/20 | 0.73 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.73 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.73 |
| ▸ | DRD3 | P35462 | 1/20 | 0.73 |
| ▸ | HTR2B | P41595 | 1/20 | 0.73 |
| ▸ | CA12 | O43570 | 1/20 | 0.73 |
| ▸ | CA1 | P00915 | 1/20 | 0.73 |
| ▸ | CA2 | P00918 | 1/20 | 0.73 |
| ▸ | CA4 | P22748 | 1/20 | 0.73 |
| ▸ | CA6 | P23280 | 1/20 | 0.73 |
| ▸ | CA5A | P35218 | 1/20 | 0.73 |
| ▸ | CA7 | P43166 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8178893 | 0.99 | DRD2 (0.72) | DRD2HTR2ADRD4HTR1AADRA2A | |
| SCHEMBL7404186 | 0.96 | DRD2 (0.68) | DRD2HTR2ADRD4HTR1AADRA2A | |
| SCHEMBL8303911 | 0.96 | DRD2 (0.68) | DRD2HTR2ADRD4HTR1AADRA2A | |
| SCHEMBL7400213 | 0.94 | DRD2 (0.64) | DRD2HTR2ADRD4HTR1AADRA2A | |
| SCHEMBL7395270 | 0.91 | DRD2 (0.67) | DRD2HTR2ADRD4HTR1AADRA2A | |
| SCHEMBL7395787 | 0.91 | DRD2 (0.72) | DRD2HTR2ADRD4HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL7394797 | 0.90 | DRD2 (0.70) | DRD2HTR2ADRD4HTR1AADRA2A | |
| SCHEMBL8551188 | 0.88 | HTR1D (0.78) | DRD2HTR2ADRD4HTR1AADRA2A | |
| SCHEMBL7398463 | 0.87 | DRD2 (0.79) | DRD2HTR2ADRD4HTR1AADRA2A | |
| SCHEMBL5698946 | 0.86 | DRD2 (0.82) | DRD2HTR2ADRD4HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1638739-A | Compounds for the treatment of addictive disorders | UPJOHN CO (US) | 2005-07-13 | — | — | CN | claimed |
| EP-1363634-A2 | COMPOUNDS FOR THE TREATMENT OF ADDICTIVE DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-26 | — | — | EP | claimed |
| US-20030078273-A1 | Compounds for the treatment of addictive disorders | ANDERSON RICHARD W (US) | 2003-04-24 | — | — | US | claimed |
| US-20020049206-A1 | Compounds for the treatment of addictive disorders | PHARMACIA & UPJOHN (A DELAWARE CORPORATION) | 2002-04-25 | — | — | US | claimed |
| WO-2002013807-A2 | COMPOUNDS FOR THE TREATMENT OF ADDICTIVE DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-21 | — | — | WO | claimed |
| EP-0737189-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | UPJOHN CO (US) | 1999-07-28 | — | — | EP | claimed |
| EP-0737189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 1996-10-16 | — | — | EP | claimed |
| WO-1995018118-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | THE UPJOHN COMPANY (US) | 1995-07-06 | — | — | WO | claimed |
| EP-1685838-A1 | Compounds for the treatment of addictive disorders | Pharmacia & Upjohn Company LLC (US) | 2006-08-02 | — | — | EP | disclosed |
| CN-1638739-A | Compounds for the treatment of addictive disorders | UPJOHN CO (US) | 2005-07-13 | — | — | CN | disclosed |
| US-6841557-B2 | Compounds for the treatment of addictive disorders | PHARMACIA & UPJOHN (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1363634-A2 | COMPOUNDS FOR THE TREATMENT OF ADDICTIVE DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030078273-A1 | Compounds for the treatment of addictive disorders | ANDERSON RICHARD W (US) | 2003-04-24 | — | — | US | disclosed |
| US-20020049206-A1 | Compounds for the treatment of addictive disorders | PHARMACIA & UPJOHN (A DELAWARE CORPORATION) | 2002-04-25 | — | — | US | disclosed |
| WO-2002013807-A2 | COMPOUNDS FOR THE TREATMENT OF ADDICTIVE DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
| US-6133446-A | Heterocyclic compounds for the treatment of CNS and cardiovascular disorders | PHARMACIA & UPJOHN COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0737189-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | UPJOHN CO (US) | 1999-07-28 | — | — | EP | disclosed |
| EP-0737189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995018118-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | THE UPJOHN COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049206-A1 | Compounds for the treatment of addictive disorders | OPRK1, SLC6A3, TACR2 | DRD2 11/4885HTR2A 128/4885DRD4 76/4885 |
| US-20030078273-A1 | Compounds for the treatment of addictive disorders | OPRK1, SLC6A3, TACR2 | DRD2 11/4885HTR2A 128/4885DRD4 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.